✦ LIBER ✦

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience

✍ Scribed by Michael B. Sprakes; Alexander C. Ford; Lisa Warren; Dan Greer; John Hamlin

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and tolerability of methotrexat

✍ N. C. Suares; P. J. Hamlin; D. P. Greer; L. Warren; T. Clark; A. C. Ford 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB

Adalimumab for Crohn’s disease with into

✍ A. OUSSALAH; A. BABOURI; J.-B. CHEVAUX; L. STANCU; I. TROUILLOUD; M. BENSENANE; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB

Efficacy and safety of infliximab and ad

✍ F. Zorzi; S. Zuzzi; S. Onali; E. Calabrese; G. Condino; C. Petruzziello; M. Asco 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 472 KB

Predictors of Sustained Response to Infl

✍ Duricova, Dana ;Malickova, Karin ;Bortlik, Martin ;Machkova, Nadezda ;Komarek, V 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 38 KB

Costs of care for Crohn’s disease follow

✍ M. B. Sprakes; A. C. Ford; N. C. Suares; L. Warren; D. Greer; C. F. Donnellan; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB

Open-label infliximab therapy in Crohn's

✍ Yago González-Lama; Antonio López-San Román; Ignacio Marín-Jiménez; Begoña Casis 📂 Article 📅 2008 🏛 Elsevier Science 🌐 Spanish ⚖ 98 KB